Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple ultrasound replace MRI for spotting dangerous prostate cancer?

NCT ID NCT06183905

Diagnosis Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study compares two imaging methods—multiparametric ultrasound (mpUS) and multiparametric MRI (mpMRI)—to see which better detects clinically significant prostate cancer in men scheduled for their first biopsy. Participants receive both scans before biopsy, and if either shows a suspicious area, targeted biopsies are taken alongside standard systematic samples. The goal is to determine whether the less expensive and more widely available ultrasound can match MRI's accuracy in finding aggressive cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multiparametric ultrasound (mpUS) imaging
What this could lead to
If mpUS proves as accurate as MRI, it could offer a faster, cheaper, and more accessible way to detect significant prostate cancer, reducing the need for MRI scans.
What could go wrong
Ultrasound may not match MRI's sensitivity, and results depend on operator skill. This is a single-center study, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

635 people

The number who actually took part.

Started

Dec 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Scheduled for prostate biopsy; 2. Signed the informed consent. Exclusion Criteria: 1. Contraindications to MRI, such as metal implants, claustrophobia, etc; 2. Contraindications to ultrasound, such as acute myocardial infarction, acute cerebral infarction and rectal tumor after Miles operation; 3. Contraindications of prostate biopsy, such as abnormal routine urine test, coagulation function and electrocardiogram 4. Any medical condition or other event that may significantly reduce the chances of obtaining reliable data, achieving the purpose of the study or completing the study and follow-up; 5. The study doctor thinks it is not suitable to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate biopsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate biopsy Prostate cancer

Contacts and locations

Locations

  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200092, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.